dr reddy's glp-1 drugs portfolio 2025 Reddys eyes global market with generic drug rollout on patent expiry | Hyderabad News We are pleased to welcome

Lilly CEO Dave Ricks recently noted that Foundayo is not more effective than the companys injectable Zepbound, he told CNBC, but its more accessible, its easier to fit into your daily routine. In ATTAIN-1 trials, patients on the highest dose lost an average of 12.4% of their body weight over 72 weeks, compared to the 20%-plus weight loss typically seen with injectable tirzepatide

Recovery markers: soreness lasting more than 48 hours, sleep quality, and energy for daily physical activity

Diabetes type 2 Educational content only not medical advice

And thats a change from where weve been in terms of treating obesity. For practitioners looking to deepen their expertise in GLP-1 medications, IAPAM offers specialized training programs designed to help physicians understand and integrate these therapies into their aesthetic medicine practices